Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 3.41%1.83B | -3.36%398.13M | 3.45%528.53M | 8.99%451.04M | 4.49%448.94M | 7.44%1.77B | -2.60%411.95M | -1.37%510.91M | 15.36%413.84M | 24.80%429.66M |
Operating revenue | 3.41%1.82B | -3.36%397.36M | 3.50%527.49M | 8.99%449.82M | 4.42%448.3M | 7.43%1.76B | -2.64%411.19M | -1.44%509.64M | 15.39%412.73M | 24.84%429.34M |
Cost of revenue | 3.12%1.49B | -5.14%355M | 2.66%394.12M | 4.89%347.02M | 10.58%398.64M | 10.32%1.45B | 2.50%374.25M | -1.41%383.92M | 19.62%330.83M | 27.50%360.51M |
Gross profit | 4.74%331.85M | 14.40%43.13M | 5.85%134.41M | 25.32%104.02M | -27.27%50.29M | -4.02%316.84M | -34.81%37.7M | -1.26%126.98M | 1.05%83.01M | 12.38%69.15M |
Operating expense | 19.26%4.01M | 104.94%1.87M | 0.58%698K | 5.47%752K | -33.40%696K | 14.69%3.36M | -13.73%911K | 84.08%694K | 11.58%713K | 21.37%1.05M |
Other operating expenses | 19.26%4.01M | 104.94%1.87M | 0.58%698K | 5.47%752K | -33.40%696K | 14.69%3.36M | -13.73%911K | 84.08%694K | 11.58%713K | 21.37%1.05M |
Operating profit | 4.58%327.84M | 12.15%41.26M | 5.88%133.71M | 25.49%103.27M | -27.18%49.6M | -4.19%313.48M | -35.20%36.79M | -1.51%126.29M | 0.97%82.29M | 12.26%68.1M |
Net non-operating interest income expense | -11.95%-113.29M | 21.41%-13.86M | -13.71%-34.15M | -15.83%-32.46M | -28.72%-32.82M | -21.30%-101.19M | -1.25%-17.64M | -32.02%-30.03M | -28.84%-28.03M | -18.59%-25.5M |
Non-operating interest income | 47.89%22.58M | ---- | ---- | ---- | ---- | 156.49%15.27M | ---- | ---- | ---- | ---- |
Non-operating interest expense | 16.67%135.87M | 10.74%36.44M | 13.71%34.15M | 15.83%32.46M | 28.72%32.82M | 30.30%116.46M | 40.78%32.91M | 32.02%30.03M | 28.84%28.03M | 18.59%25.5M |
Other net income (expense) | 17.62%90.45M | -35.48%6.78M | 32.26%30.64M | 19.24%27.1M | 26.48%25.94M | 43.34%76.9M | -3.46%10.5M | 39.53%23.16M | 73.15%22.73M | 57.28%20.51M |
Earnings from equity interest | -63.47%4.54M | -78.32%659K | -52.85%1.98M | -53.38%1.28M | -74.53%625K | 7.95%12.43M | 7.88%3.04M | 2.37%4.2M | 19.71%2.74M | 6.33%2.45M |
Special income (charges) | 22.90%63.42M | 22.25%23.81M | 37.44%15.18M | 18.85%13.28M | 12.56%11.15M | 16.25%51.61M | 17.92%19.48M | 16.73%11.04M | 20.31%11.17M | 8.60%9.91M |
-Less:Other special charges | -22.90%-63.42M | -22.25%-23.81M | -37.44%-15.18M | -18.85%-13.28M | -12.56%-11.15M | -16.25%-51.61M | -17.92%-19.48M | -16.73%-11.04M | -20.31%-11.17M | -8.60%-9.91M |
Other non- operating income (expenses) | 74.72%22.49M | -47.26%-17.7M | 70.09%13.48M | 42.30%12.55M | 73.83%14.17M | 671.07%12.87M | -42.06%-12.02M | 160.49%7.92M | 468.41%8.82M | 406.15%8.15M |
Income before tax | 5.47%305M | 15.25%34.18M | 9.02%130.2M | 27.16%97.91M | -32.32%42.72M | -2.76%289.19M | -40.97%29.65M | -2.18%119.42M | 5.65%77M | 20.89%63.12M |
Income tax | -44.85%15.05M | -124.35%-3.82M | 18.76%16.36M | -0.84%8.06M | -178.17%-5.55M | -27.87%27.3M | -121.10%-1.7M | -10.85%13.77M | -1.93%8.13M | 17.74%7.1M |
Net income | 10.71%289.95M | 21.18%38M | 7.76%113.84M | 30.47%89.84M | -13.84%48.27M | 0.90%261.89M | -25.62%31.36M | -0.92%105.65M | 6.62%68.86M | 21.31%56.02M |
Net income continuous Operations | 10.71%289.95M | 21.18%38M | 7.76%113.84M | 30.47%89.84M | -13.84%48.27M | 0.90%261.89M | -25.62%31.36M | -0.92%105.65M | 6.62%68.86M | 21.31%56.02M |
Minority interest income | 11.32%777K | 24.24%123K | -38.64%235K | 11.72%324K | 228.38%95K | 20.76%698K | -5.71%99K | 54.44%383K | -3.65%290K | 2.63%-74K |
Net income attributable to the parent company | 10.71%289.17M | 21.17%37.88M | 7.92%113.61M | 30.55%89.52M | -14.13%48.17M | 0.85%261.2M | -25.67%31.26M | -1.05%105.26M | 6.67%68.57M | 21.27%56.1M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | 10.71%289.17M | 21.17%37.88M | 7.92%113.61M | 30.55%89.52M | -14.13%48.17M | 0.85%261.2M | -25.67%31.26M | -1.05%105.26M | 6.67%68.57M | 21.27%56.1M |
Basic earnings per share | 6.80%5.5 | 9.68%0.68 | 2.40%2.13 | 27.41%1.72 | -14.41%0.95 | 0.78%5.15 | -25.30%0.62 | -0.95%2.08 | 6.30%1.35 | 21.98%1.11 |
Diluted earnings per share | 7.00%5.5 | 11.48%0.68 | 2.42%2.12 | 26.67%1.71 | -14.41%0.95 | 0.59%5.14 | -26.51%0.61 | -1.43%2.07 | 6.30%1.35 | 21.98%1.11 |
Dividend per share | 4.69%3.35 | 3.61%0.86 | 5.06%0.83 | 5.06%0.83 | 5.06%0.83 | 5.26%3.2 | 5.06%0.83 | 5.33%0.79 | 5.33%0.79 | 5.33%0.79 |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |